Sublingual Cannabidiol for Anxiety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02548559|
Recruitment Status : Not yet recruiting
First Posted : September 14, 2015
Last Update Posted : December 18, 2017
|Condition or disease||Intervention/treatment||Phase|
|Anxiety||Drug: Cannabidiol||Phase 2|
Cannabis has been used for medicinal purposes across many cultures for a range of disorders dating as far back as 2700 B.C. The plant is comprised of a variety of components, including phytocannabinoids that act on CB1 and CB2 receptors. Numerous phytocannabinoids are present in cannabis, including the major psychoactive constituent of cannabis, delta-9 tetrahydrocannabinol (THC), which acts as a CB1 receptor agonist. Another phytocannabinoid, cannabidiol (CBD), is a major non-psychoactive constituent of cannabis and is only a partial agonist at CB1 receptors. Increasing evidence indicates that CBD in particular may have significant medicinal properties and benefits; experimental studies in both animals and humans have demonstrated that CBD can act as an anticonvulsant, antipsychotic, and muscle relaxant. CBD is often found in higher levels in products dispensed as medical marijuana relative to strains used primarily for recreational use. Several studies have demonstrated that CBD produces acute anxiolytic effects in animals and humans, although thus far no clinical trials of CBD have been conducted in patients with anxiety. As a growing number of states are legalizing medical marijuana, a gap exists in the scientific literature regarding the effects of CBD on anxiety.
This investigation is composed of two phases. Phase 1 is comprised of a four-week, open label clinical trial of a high-CBD containing compound (22:1 CBD:THC) in individuals with anxiety. Participants will be pre-screened by phone in order to evaluate their eligibility for the study. If approved, participants will come to the hospital for a baseline/screening visit, and will complete a structured clinical interview, clinical and quality of life questionnaires, cognitive assessments, and an hour-long MRI scan. Enrolled participants will be given tincture to use for the duration of the study; participants will be instructed to self-administer 2 milliliters (ml) of the tincture under the tongue three times per day for four weeks. Throughout the treatment period, participants will return to the hospital on a weekly basis to complete questionnaires about their mood and quality of life. Participants will also return to the hospital for a final visit after four weeks of treatment to complete additional questionnaires, cognitive assessments, and another hour-long MRI scan.
Phase 2 of the study is a double-blind clinical trial of this tincture in patients with anxiety. This double-blind trial will begin after the open-label trial has been completed. In the same manner as the open-label trial, participants will be pre-screened by phone, and approved participants will come to the hospital for a baseline/screening visit to complete a structured clinical interview, questionnaires, and cognitive assessments. Eligible participants will also have the option to complete an hour-long MRI scan at the baseline and final visits. Enrolled participants will receive either CBD tincture or placebo tincture to self-administer throughout the four week treatment period, as described above. Participants will return to the hospital weekly during the treatment period to complete questionnaires about their mood and quality of life. Participants in this phase of the study will also return for a final visit after four weeks of treatment to complete additional questionnaires, cognitive assessments, and an optional hour-long MRI scan.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Sublingual Cannabidiol for Anxiety|
|Anticipated Study Start Date :||March 2018|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
2ml of sublingual cannabidiol tincture (4.68mg/ml CBD) administered three times per day (TID) for four weeks.
Cannabidiol; total daily dose of 28.08mg.
- Change from Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI) [ Time Frame: Week 1, Week 2, Week 3, Week 4 ]The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3, and will be given to participants on a weekly basis.
- Change from Baseline in Anxiety Assessed by the Hamilton Anxiety Scale (HAM-A) [ Time Frame: Week 1, Week 2, Week 3, Week 4 ]The HAM-A is an administered measure of anxiety that will be given on a weekly basis; a variety of symptoms are rated on a scale of 0 to 4.
- Change from Baseline in Self-Reported Anxiety Assessed by the State-Trait Anxiety Inventory (STAI) [ Time Frame: Week 1, Week 2, Week 3, Week 4 ]This self-report measure is comprised of two 20-item scales, with a range of four possible responses from 1 to 4, and differentiates between the more temporary condition of "state" anxiety and the more general quality of "trait" anxiety. It will be given on a weekly basis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02548559
|Contact: Staci Gruber, PhD.||email@example.com|
|United States, Massachusetts|
|McLean Hospital Brain Imaging Center||Not yet recruiting|
|Belmont, Massachusetts, United States, 02478-9106|
|Contact: Staci Gruber, PhD 617-855-2762 firstname.lastname@example.org|
|Principal Investigator: Staci A Gruber, Ph.D.|
|Sub-Investigator: David P Olson, M.D., Ph.D.|
|Sub-Investigator: Scott E Lukas, Ph.D.|